Best Clinical Genomics Companies in Pennsylvania, United States
The 33 best Clinical Genomics companies in Pennsylvania, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Helomics.
Ranked: Best Clinical Genomics companies in Pennsylvania
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Helomics AI-driven platform to develop precisely targeted therapies for cancer patients | $196M | 102 mo ago | Acquired | — | 13 | — | 2 patents Personalized oncology diagnostics and in vitro chemotherapy response simulation platforms | — |
| 2 | Nucleonics Developing RNAi therapeutics for Hepatitis B and C, using eiRNA technology | $52M | 264 mo ago | Acquired | John Maraganore CEO | — | — | 46 patents RNAi-based antiviral therapeutics and gene-silencing platforms targeting hepatitis viruses | — |
| 3 | Saladax Therapeutic drug monitoring assays improving patient outcomes in psychiatry and oncology | $46M | 157 mo ago | Series D | Salvatore Salamone President and CEO | 17 17 → 25 (+47%) | — | — | — |
| 4 | Instadiagnostics Point-of-care diagnostics platform delivering rapid, comprehensive healthcare solutions | $11M | 17 mo ago | Funding Raised | Johann deSa Founder | 5 | — | — | — |
| 5 | Jbs-science Provider of circulating cell-free DNA (cfDNA) for cancer screening | $10M | 18 mo ago | Funding Raised | Frank Song Founder | — | — | — | — |
| 6 | Molecular Detection Molecular diagnostics company focused on rapid, accurate infectious disease detection | $8M | 160 mo ago | Deadpooled | Aryeh Gassel Co-Founder | — | — | 26 patents Rapid PCR-based molecular diagnostics for antibiotic‑resistant bacterial detection | — |
| 7 | ARIEL Precision Medicine Precision medicine for complex diseases through advanced genetics and data analysis | $6M | 87 mo ago | Series A | — | 22 | WordPressMySQLPHP+29 | — | — |
| 8 | Biomeme Developer of a smartphone-based DNA detection platform | $6M | 114 mo ago | Series A | — | 202 | Tailwind CSSAmazon Web ServicesAstro+5 | 89 patents Point‑of‑care nucleic acid sample preparation and rapid molecular diagnostic devices | — |
| 9 | Rosetta Genomics MicroRNA-based molecular diagnostics, research laboratory, and testing services for cancer | $4M | 111 mo ago | Acquired | — | 86 | — | 28 patents MicroRNA-based therapeutics targeting liver cancer | — |
| 10 | Liquid Biotech Provider of telomerase-based liquid biopsy tests | $2M | 130 mo ago | Seed | Philip Sass CEO | 2 | — | — | — |
| 11 | Leversense Developing device for detecting AIDS, food toxin and mycoplasma bacteria | $659K | 190 mo ago | Deadpooled | Paul Horan ex-CEO | — | — | 4 patents Patents concentrated in computing, sensing & instrumentation | — |
| 12 | MS2 Array Online platform offering microarray services | $222K | 109 mo ago | Funding Raised | Marvin S. Yu Co-Founder & CEO | 1 | — | — | — |
Top 12 Clinical Genomics companies in Pennsylvania
#1
Funding Raised · Philadelphia, Pennsylvania · founded 2015 · 5 employees$11Mraised▾
Point-of-care diagnostics platform delivering rapid, comprehensive healthcare solutions. The company provides a diagnostic technology platform designed to empower healthcare professionals with the capability to perform various tests directly at their clinics. This innovative system utilizes a portable, multi-modality reader and application-specific cartridges to deliver timely, accurate, and comprehensive healthcare within a single visit. The platform supports immunoassay, chemistry, and molecular assays, as well as complete blood cell counts. The fully automated system minimizes user errors and provides rapid results, enhancing efficiency and improving patient outcomes. This technology offers a single device solution, reducing the need for multiple systems and extensive training. The platform features wireless connectivity and electronic medical record compatibility, facilitating seamless integration into existing healthcare workflows. This is a B2B tech company in the healthcare industry.
- May 2025Grant (prize money)$4.1M
- Sep 2021Grant (prize money)$1M
- Jul 2020Grant (prize money)$4.1M
- Feb 2020Grant (prize money)$225K
#2
Funding Raised · Pennsylvania Furnace, Pennsylvania · founded 2011$10.4Mraised▾
Provider of circulating cell-free DNA (cfDNA) for cancer screening. The company has developed qPCR assays for tumor DNA markers using cfDNA in urine and blood, and robust methods for cfDNA isolation. The first application is the non-invasive screening and monitoring of hepatocellular carcinoma. Additional diagnostic tests for colon, pancreatic, and lung cancer are also under development.
- Apr 2025Grant (prize money)$604.2K
- Aug 2023Grant (prize money)$406.5K
- Mar 2023Grant (prize money)$595.8K
- Dec 2021Grant (prize money)$604.2K
#3
Acquired · Pittsburgh, Pennsylvania · founded 1995 · 13 employees$195.6Mraised▾
AI-driven platform to develop precisely targeted therapies for cancer patients. The company has a proprietary technology platform and data pipeline that provides next-generation, AI- and data-driven services to Pharma and Diagnostic companies to accelerate the development of new precision therapies.
- Apr 2018Series E$3M
- May 2017Series E$110K
- Mar 2017Series E$2M
- Nov 2014Series E$60M
#4
Series D · Bethlehem, Pennsylvania · founded 2004 · 17 employees$46.3Mraised▾
Therapeutic drug monitoring assays improving patient outcomes in psychiatry and oncology. They develop and manufacture assays for essential and life-saving medications, ensuring optimal dosing for each patient. This personalized medicine approach helps healthcare professionals make timely treatment decisions, accounting for individual variations in drug metabolism. Their assays aim to improve outcomes, reduce toxicity risks, and potentially shorten hospital stays. They also collaborate with pharmaceutical companies to develop tests for clinical trials and companion diagnostics. Their offerings support healthcare professionals in both oncology and psychiatry, providing vital information for effective therapeutic drug management. They focus on precision treatment and addressing unmet medical needs in drug monitoring.
- Sep 2013Series D$22.9M
- Jun 2011Conventional Debt$9M
- Mar 2010Series C$8.4M
- Oct 2009Series B$7.9M
#5
Acquired · Langhorne, Pennsylvania · founded 2001$51.9Mraised▾
Developing RNAi therapeutics for Hepatitis B and C, using eiRNA technology. The company focuses on addressing unmet clinical needs in treating chronic viral infections. Their eiRNA technology enables novel therapeutic options that interfere with viral function while providing a more favorable toxicity profile. They engineer drug candidates to be effective against all genotypes, resistant to viral escape mutants, and compatible with existing therapies. The company utilizes a multi-targeted approach with short hairpin RNA molecules to mediate the destruction of viral RNA. They also focus on DNA delivery and manufacturing technology, using proprietary formulations of cationic lipids to deliver RNAi molecules to target cells.
- Oct 2004Series B$2.7M
- Jun 2004Series B$8.3M
- Apr 2004Series B$40.9M
#6
Series A · Pittsburgh, Pennsylvania · founded 2013 · 22 employees$6.5Mraised▾
Precision medicine for complex diseases through advanced genetics and data analysis. The company transforms genetic and clinical data into insights for diagnosis, management, and therapeutic development for complex health conditions. They go beyond genetics, integrating lifestyle and environmental factors for a comprehensive view of disease trajectory and precise therapeutic options. Their platform combines genetics, environmental, and patient-specific data with clinical guidance to provide actionable risk assessment for early detection, risk-reducing strategies, and treatment. They offer multi-gene DNA sequencing panels to identify genetic mechanisms driving disease. Their genetic segmentation platform enables patient-specific treatment decisions based on systems biology, evidence-based medicine, genetic linkages, and domain expertise. They strive to help clinicians make informed decisions about treating complex chronic diseases. They offer login functionality and insights through guides and webinars. They are a tech company using software and data science to improve healthcare outcomes.
- Jul 2019Series A$5.3M
- Nov 2017Seed$1M
- Apr 2017Seed$100K
- May 2016Seed$125K
#7
Series A · Philadelphia, Pennsylvania · founded 2013 · 202 employees$6.2Mraised▾
Developer of a smartphone-based DNA detection platform. The platform transforms mobile labs for advanced DNA diagnostics and real-time disease surveillance. The system includes a docking station for real-time qPCR, a mobile app to control the system and analyze results, and targeted test kits for preparing samples and identifying pathogens or diseases by their specific DNA or RNA signatures. The first application is a panel for diagnosing sexually transmitted diseases.
- May 2017Series A$4.5M
- Sep 2016Grant (prize money)$56.1K
- Jun 2016Grant (prize money)$55.9K
- Feb 2014Seed$400K
#8
Deadpooled · Philadelphia, Pennsylvania · founded 2007$8.3Mraised▾
Molecular diagnostics company focused on rapid, accurate infectious disease detection, developing and commercializing sample-to-answer molecular diagnostic tests. They leverage proprietary technologies to increase the speed, accuracy, ease of use, and efficiency of infectious disease diagnosis. Their Detect-Ready assays target the rapid detection of infectious diseases, including MRSA, C. difficile, STDs, and foodborne pathogens. The company's real-time PCR tests are designed for increased accuracy and faster results, simplifying assay storage and use. Their patent-pending technologies provide a differential diagnosis engine to identify specific pathogens and differentiate them from other infectious sources, covering methods for detecting antibiotic-resistant strains. This innovative approach aims to provide cost-effective solutions for healthcare settings.
- 2013Series B—
- Apr 2012Series B$1.9M
- Mar 2012Series B$1.5M
- Jun 2010Series A$1.4M
#9
Acquired · Philadelphia, Pennsylvania · founded 2000 · 86 employees$4Mraised▾
MicroRNA-based molecular diagnostics, research laboratory, and testing services for cancer. It focuses on human molecular diagnostics, offering a range of products and services including peptides, PCR, NATtrol particles, RNA, Ria Kits, recombinant proteins, reagents, test kits, and Western blot analysis. The company supports research with lab reagents, monoclonals, and assays. It provides molecular profiling services, quantum state identification, and molecular evolutionary genetics analysis. The business model is B2B, serving research and diagnostic sectors with tools for molecular biology, genetics, and precision medicine. It offers multiple products and services, including diagnostic kits and reagents, catering to diverse research needs.
- Jul 2017Grant (prize money)—
- Aug 2013Grant (prize money)—
- Feb 2012Post IPO$1.8M
- Oct 2011Post IPO$1.5M
#10
Seed · Audubon, Pennsylvania · founded 2015 · 2 employees$2Mraised▾
Provider of telomerase-based liquid biopsy tests. The company's proprietary technology uses recombinant viral vectors that trigger fluorescence in circulating tumor cells based on the level of telomerase activity.
- Dec 2015Seed$2M
#11
Deadpooled · Newtown Square, Pennsylvania · founded 2009$659Kraised▾
Leversense, intends to develop a medical device for detecting AIDS, food toxin, and mycoplasma bacteria. The company was incorporated in 2009 and is based in Newtown Square, Pennsylvania.
- Dec 2010Seed$399K
- Jul 2009Seed$260K
#12
Funding Raised · Pittsburgh, Pennsylvania · founded 2012 · 1 employees$221.8Kraised▾
Online platform offering microarray services. The company provides high-throughput screening (HTS) services utilizing its high-throughput mass spectrometry (HT-MS) technology to provide a label-free assay platform for epigenetics, kinases, proteases, phosphatases, and other enzyme activity assays. The services offered by the company comprise of materials and expertise needed for you to employ the MS2 Array technology in your automated spotting and MALDI-MS system. This includes the fluorous capture surface, and fluorous assay substrates, along with protocol development to provide information-rich HTS output.
- Sep 2017Grant (prize money)$221.8K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding flat · growth rising
How research on Diagnostics in Pennsylvania is moving
A read on the academic research around Diagnostics in Pennsylvania — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 148 papers.
- University of Pennsylvania101
- Pennsylvania State University29
- Hospital of the University of Pennsylvania14
- California University of Pennsylvania11
- University of Pennsylvania Health System3
- Loop-mediated isothermal amplification1→3
- Point-of-care testing4→5
- Biopsy1→9
- Point-of-care testing2→8
- Liquid biopsy6→11
- Point of care1→6
- Circulating tumor cell3→5
- Point-of-care testing11
- Liquid biopsy10
- Point of care7
- Biopsy7
- Human immunodeficiency virus (HIV)5
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.